Abstract

Here, we present a highly sensitive method to study protein-protein interactions and subcellular location selectively for active multicomponent enzymes. We apply the method on γ-secretase, the enzyme complex that catalyzes the cleavage of the amyloid precursor protein (APP) to generate amyloid β-peptide (Aβ), the major causative agent in Alzheimer disease (AD). The novel assay is based on proximity ligation, which can be used to study protein interactions in situ with very high sensitivity. In traditional proximity ligation assay (PLA), primary antibody recognition is typically accompanied by oligonucleotide-conjugated secondary antibodies as detection probes. Here, we first performed PLA experiments using antibodies against the γ-secretase components presenilin 1 (PS1), containing the catalytic site residues, and nicastrin, suggested to be involved in substrate recognition. To selectively study the interactions of active γ-secretase, we replaced one of the primary antibodies with a photoreactive γ-secretase inhibitor containing a PEG linker and a biotin group (GTB), and used oligonucleotide-conjugated streptavidin as a probe. Interestingly, significantly fewer interactions were detected with the latter, novel, assay, which is a reasonable finding considering that a substantial portion of PS1 is inactive. In addition, the PLA signals were located more peripherally when GTB was used instead of a PS1 antibody, suggesting that γ-secretase matures distal from the perinuclear ER region. This novel technique thus enables highly sensitive protein interaction studies, determines the subcellular location of the interactions, and differentiates between active and inactive γ-secretase in intact cells. We suggest that similar PLA assays using enzyme inhibitors could be useful also for other enzyme interaction studies.

Highlights

  • Introduction c-Secretase has been extensively studied as it catalyzes the final step in generation of the neurotoxic amyloid b-peptide (Ab), which is involved in the development of Alzheimer disease (AD) [1]

  • Discussion c-Secretase is a potential target for AD treatments, since it cleaves the amyloid precursor protein (APP) to generate the neurotoxic Ab peptide

  • Clinical trials with c-secretase inhibitors have shown disappointing results, mainly due to toxic side effects caused by inhibited c-secretase processing of other substrates than APP, for instance Notch

Read more

Summary

Introduction

Secretase has been extensively studied as it catalyzes the final step in generation of the neurotoxic amyloid b-peptide (Ab), which is involved in the development of Alzheimer disease (AD) [1]. It is composed of the four protein subunits presenilin 1 (PS1) or 2 (PS2), nicastrin, anterior pharynx-defective phenotype 1 (Aph-1) and PSenhancer 2 (Pen-2). The relatively small protein, Pen-2 (containing two TM domains), joins the complex and facilitates auto-proteolytic cleavage of PS to generate an N-terminal (NTF) and a C-terminal fragment (CTF), which is required to generate active c-secretase [9]. Knowledge about the subcellular location of active c-secretase could for instance be used for subcellular targeting of the active enzyme

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.